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(VMAT). We present our clinical experience in the first patients (> 6 
months follow-up) to emphasize tolerance to low dose exposure. 
Materials and Methods: We reviewed 198 patients (mean age 55 range 
32-75): 121 were treated for left sided, 72 right sided and 5 for 
bilateral disease. Approximately half of the patients had an indication 
for lymph node irradiation. Patients were treated with an integrated 
boost (SIB) of 50.4/64.4Gy (n=89) or 50/#2Gy(n=32) or with 
42.6/#2.66Gy (START) and 10/#2.5Gy sequential boost (n=66). Sixteen 
patients (> 70 yrs) received 5x (+2x boost) 6.5 Gy weekly. Patients 
were seen weekly and at 1, 3 and 6 month after treatment. Potential 
risk factors for toxicity were tested in 2x2 tables (Fisher´s exact). The 
planning target volume dose was prescribed 95% (maximum< 108%), 
with objectives for respectively, ipsilateral lung (V20Gy<20-30%, 
V5Gy<60-65%), other lung (V5Gy<20%), heart (V10Gy<50%, V35Gy<10%) 
with maximum <35Gy, and contralateral breast (V5Gy<0.5-1%)with 
maximum <10Gy. All dose volume comparisons were adjusted to 
abiological equivalent dose of 2Gy/ fraction.  
Results: During planning VMAT plans were often abandoned (85%) 
mainly because of V5, and alternative IMRT was selected for 
treatment. VMAT plans selected for treatment resulted in higher V10 
in heart (19.7 versus 13.7%), V5 of contralateral breast (0.8 versus 
0.4%) and lung V5 (66.8 versus 63.8). For bilateral, however, VMAT 
resulted in better dose distributions. One bilateral treatment 
consistedof SIB, all others of START, being easier to set up and better 
tolerated. Almost no dermatitis (13% grade 2) or cosmetic 
deterioration was observed. Dry cough was observed in 18% of patients 
and 8 patients) needed medication (pneumonitisgrade 2 RTOG). Plans 
were reviewed and those patients with dry cough showed oftenlung V5 
over 70%. Among other risk factors tested (table 1) lung V5 exposure 
over 70% appeared strongly associated with pneumonitis. After the 
first analysis, we decided to not accept any planning with V5 over 70% 
and no new clinical pneumonitis has appeared since.  
  
Conclusions: IMRT results in less V5 exposure than VMAT planning of 
breast patients. High V5 lung values clearly increase pneumonitis risk. 
More research on low dose exposure is needed to create guidelines for 
dose constraints. Systematic comparison of IMRT to VMAT can 
optimize future planning in breast cancer patients. 
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Purpose/Objective: The development of proton and ion acceleration 
by ultra high intensity lasers for cancer therapy promises the 
realization of compact and economic particle accelerators that can be 
integrated in already existing clinics. For translational research 
towards clinical application the radiobiological consequences of laser 
accelerated and therewith ultra-short pulsed particle beams with high 
pulse dose have to be investigated. After extensive in vitro dose 
response studies with laser driven electron and proton beams, in vivo 
experiments have been performed within the joint research project 
'onCOOPtics' as next translational step. 
Materials and Methods: A mouse tumor model suitable for currently 
available low energy laser protons was developed, tested and 
successfully used. The already in vitro established laser based 
irradiation technology was further developed for the animal model in 
terms of beam transport, beam monitoring, dose delivery and 
dosimetry allowing to apply a prescribed dose to each tumor and to 
determine the absolute dose received. For precise and reproducible 
positioning at the irradiation site a system for mouse fixation, tumor 
positioning and position verification was implemented as described in 
[Schürer et al 2012]. Experiments were carried out at the 30 Terawatt 
Jena Titanium:Sapphire (JeTi) laser system. Laser pulses of 28 fs 
duration were focused into a hydrogen gas jet accelerating electrons 
to energies of up to a few 10 MeV. In vivo tumor irradiation was 
realized for murine sarcoma KHT and human squamous cell carcinoma 
FaDu. Dose sup to 14 Gy were applied at mean dose rates of 1-2 
Gy/min and irradiation induced tumor growth delay was investigated. 
Comparison irradiations were performed at a conventional therapy 
LINAC with the same setup for irradiation and absolute dose 
determination.  
Results: The reliability and stability of all implemented setup 
components and methods were proven by numerous irradiations over a 
period of several months. Dose response curves of tumor growth delay 
were generated for direct comparison of ultra short pulsed laser 
accelerated and conventional continuous electron beam. The ongoing 
data evaluation by now shows no significant difference in RBE for laser 
driven electrons. 
Conclusions: The successful establishment of all technical 
requirements for and the world wide first performance of systematic 
animal studies with laser accelerated electrons mark an important 
step towards the clinical application of laser accelerated particle 
beams. The realization of in vivo studies with laser driven proton 
beams is now feasible.  
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Purpose/Objective: For treatment planning with carbon ions, the 
local effect model (LEM) is used to predict the relative biological 
effectiveness (RBE) in normal and tumor tissue. Uncertainties in the 
predicted RBEs translate into uncertainty of the prescribed dose, 
which can lead to severe side effects. Therefore, the RBE-models have 
to be validated using experimental data. In a previous study in rat [1], 
the RBE for late reactions of the cervical spinal cord after irradiation 
with carbon ions was measured in the entrance region and at the 
center of a 10 mm spread-out-Bragg-peak (SOBP). A significant 
dependence of the RBE and the fractionation parameter α/β on LET 
was found. Based on this study, we systematically extend this 
database to several intermediate LET-values. 
Materials and Methods: Experiments were performed at the 
experimental beam line at the Heidelberg Heavy Ion Beam Therapy 
Center (HIT). The cervical spinal cord of female Sprague-Dawley rats 
